Argitalpenak (256) RAFAEL RUBIO GARCÍA argitalpenak

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2023

  1. HIV medical care interruption among people living with HIV in Spain, 2004-2020

    AIDS, Vol. 37, Núm. 8, pp. 1277-1284

  2. Healthcare outcomes in patients with HIV infection at a tertiary hospital during the COVID-19 pandemic

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 3, pp. 149-154

  3. Post-mortem findings in Spanish patients with COVID-19; a special focus on superinfections

    Frontiers in Medicine, Vol. 10

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  3. Incidence and Severity of SARS-CoV-2 Infection in HIV-Infected Individuals during the First Year of the Pandemic

    Journal of Acquired Immune Deficiency Syndromes, Vol. 89, Núm. 5, pp. 511-518

  4. Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance

    Open Forum Infectious Diseases, Vol. 9, Núm. 11

  5. Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018

    BMC infectious diseases, Vol. 22, Núm. 1, pp. 379

  6. Management of Comorbidities in Treated HIV Infection: A Long Way to Go: HIV, comorbidities and aging

    International Journal of Antimicrobial Agents, Vol. 59, Núm. 1

  7. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. Cryptococcal infection in HIV-infected patients with CD4+ T-cell counts under 100/μL diagnosed in a high-income country: a multicentre cohort study

    Clinical Microbiology and Infection, Vol. 27, Núm. 8, pp. 1171.e1-1171.e7

  2. Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 12, pp. 3263-3271

  3. Determinants of hiv-1 late presentation in patients followed in europe

    Pathogens, Vol. 10, Núm. 7

  4. Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004–2018

    PLoS ONE, Vol. 16, Núm. 4 April

  5. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 3, pp. 738-742

  6. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2020

  1. Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

    Journal of acquired immune deficiency syndromes (1999), Vol. 85, Núm. 3, pp. 325-330

  2. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

    EBioMedicine, Vol. 55

  3. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1